Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;32(4):687-697.
doi: 10.1016/j.giec.2022.05.002. Epub 2022 Sep 7.

Endoscopic Stricturotomy and Strictureplasty

Affiliations
Review

Endoscopic Stricturotomy and Strictureplasty

Udayakumar Navaneethan et al. Gastrointest Endosc Clin N Am. 2022 Oct.

Abstract

Strictures in inflammatory bowel disease (IBD) usually occur because of long-standing inflammation and fibrosis causing luminal narrowing. Strictures in the setting of Crohn's disease (CD) can occur de novo, or in the postsurgical setting (anastomotic strictures). Historically these strictures are managed with invasive surgical procedures which may result in considerable morbidity. Endoscopic interventions for IBD complications have evolved significantly in the last decade providing a minimally invasive option. Endoscopic balloon dilation is the commonly performed technique for CD strictures. Endoscopic stricturotomy and strictureplasty are relatively novel techniques for the management of CD strictures that can achieve comparable efficacy to surgery albeit with fewer complications and a low rate of surgical interventions. Although immediate bleeding can be an adverse event as the strictures are directly targeted with precision, there is a lower rate of major adverse events including perforation. In this review, we will focus on endoscopic stricturotomy and strictureplasty in the management of strictures in CD.

Keywords: Crohn’s disease; Inflammatory bowel disease; Strictureplasty; Strictures; Stricturotomy.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have nothing to disclose. Conflict of interest Udayakumar Navaneethan is a consultant for AbbVie and Janssen. Udayakumar Navaneethan is on the speaker bureau for Takeda, AbbVie, Pfizer, BMS, and Janssen.

MeSH terms